- Login
- Register & Subscribe
- Sprache: EN FR DE
Monday 8 April 2013
GenSight Biologics, a privately-owned French company, has raised €32 million in a Series A round from a group of venture capital funds to develop a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON), a serious eye disorder.
Country: France
Friday 5 April 2013
A revolutionary T-cell immunotherapy developed by scientists at the University of Pennsylvania in the US has demonstrated a positive result in acute lymphoblastic leukaemia (ALL), an aggressive form of childhood cancer. The results of the treatment, which was administered to two patients aged seven and 10, are scheduled to appear in the 18 April 2013 edition of The New England Journal of Medicine. A summary of the study was released early on 25 March.
Country: United States
Wednesday 3 April 2013
AstraZeneca Plc said that its MedImmune biologics unit has acquired AlphaCore Pharma Inc of the US which has a product in development, ACP-501, for the acute treatment of atherosclerosis, a hardening of the artery walls following a build-up of cholesterol.
Country: United States
Monday 1 April 2013
Clavis Pharma ASA said a Phase 3 trial of its lipid-conjugated therapy for patients with acute myeloid leukaemia (AML) failed to meet its endpoint of a significant survival advantage and that all development work with the compound will be stopped.
Country: Norway
Wednesday 27 March 2013
The Swiss synthetic biology company, Evolva Holding SA, has raised CHF 31.3 million (€25.7 million) in a share placement with existing and new investors in order to support its portfolio of nutritional and pharmaceutical products.
Country: Switzerland
Wednesday 27 March 2013
CureVac GmbH has initiated a Phase 2b trial of its messenger RNA vaccine, a new treatment modality, in patients with castration-resistant prostate cancer. The trial will enrol up to 200 patients in eight European countries.
Tuesday 26 March 2013
Agennix AG has announced that it has incurred a cumulative loss of more than half of its nominal share capital and will therefore postpone the filing of its 2012 results, originally due on 28 March. The company has cash to fund operations into June 2013.
Country: Germany
Tuesday 26 March 2013
Evotec AG expects revenue to increase again this year after achieving a 9% rate of growth in 2012 and the execution of both new alliances and contract extensions. Revenue amounted to €87.3 million for the year of which milestones were €12.3 million.
Country: Germany
Tuesday 26 March 2013
The European Medicines Agency has announced an investigation into academic findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with Type 2 diabetes who take GLP-1 agonists and DPP-4 inhibitors.
Country: United Kingdom
Tuesday 26 March 2013
Shire Plc has bolstered its portfolio for the second time in two weeks with plans to acquire SARcode Bioscience Inc of the US which has a late-stage product for treating the symptoms of dry eye disease. The deal includes an upfront payment of $160 million.
Country: United States
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013